In rats with monocrotaline-induced PAH, interventions such as inhibiting HMGB1 with glycyrrhizin, suppressing YAP activation with verteporfin, and targeting PFKFB3 with 3-PO effectively halted PAH progression. This evidence concerns the gene HMGB1 and pulmonary arterial hypertension.